[Antineoplastic effects of interferons].
Shimoyama
M
M
D000818:Animals; D000970:Antineoplastic Agents; D002455:Cell Division; D002460:Cell Line; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D007371:Interferon-gamma / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy; D007943:Leukemia, Hairy Cell / Q000628:therapy; D007951:Leukemia, Myeloid / Q000628:therapy; D009101:Multiple Myeloma / Q000628:therapy; D009369:Neoplasms / Q000628:therapy*; D012514:Sarcoma, Kaposi / Q000628:therapy
D000970:Antineoplastic Agents; D007370:Interferon Type I; D007371:Interferon-gamma; D007372:Interferons